AI assistant
UroGen Pharma Ltd. — Director's Dealing 2019
Jan 10, 2019
32312_dirs_2019-01-10_e5d2fd83-da17-4856-a1ad-18a943edc942.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2019-01-01
Reporting Person: Schoenberg Mark (Chief Medical Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Ordinary Shares | 1121 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Employee Stock Option (right to buy) | $5.00 | 2023-01-20 | Ordinary Shares (122677) | Direct | |
| Employee Stock Option (right to buy) | $39.26 | 2027-12-07 | Ordinary Shares (15000) | Direct | |
| Restricted Stock Unit | $ | Ordinary Shares (12500) | Direct |
Footnotes
F1: 25% of the shares underlying the stock option vested on each of January 20, 2016, January 20, 2017 and January 20, 2018 and the remaining 25% of the shares will vest on January 20, 2019.
F2: 33.33% of the shares underlying the stock option will vest on December 7, 2019 and 8.33% of the remaining shares will vest in equal quarterly installments thereafter.
F3: 33.33% of the restricted stock unites ("RSUs") will vest on December 7, 2019 and 8.33% of the remaining RSUs will vest in equal quarterly installments thereafter.
F4: Each RSU represents a contingent right to receive one share of the Issuer's common stock.